Early-Career Awards

Your article on "early-career awards" (S. Benowitz, The Scientist, May 26, 1997, page 13) is propagating a crucial bit of mis(dis)information with the statement that National Institutes of Health R29 (FIRST) awards "are judged on the strength and justification of their untested research proposals." The fact is that R29 applicants are expected to have track records and preliminary data just as the R01 applicants are. The R29s are judged by the study sections together with R01s and if, as they eu

Written byStephen Apfelroth
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Your article on "early-career awards" (S. Benowitz, The Scientist, May 26, 1997, page 13) is propagating a crucial bit of mis(dis)information with the statement that National Institutes of Health R29 (FIRST) awards "are judged on the strength and justification of their untested research proposals." The fact is that R29 applicants are expected to have track records and preliminary data just as the R01 applicants are. The R29s are judged by the study sections together with R01s and if, as they euphemistically term it, "there is a lack of confidence in the applicant's ability to carry out the research proposals," the application will be triaged out and will never even receive a review on the merits of the research proposal, no matter how stellar it might be.

Furthermore, there is no separate grant money set aside for the R29s, so even though there may be nominal instructions to provide R29s special ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies